Analysis of Early Efficacy and Immune Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

Overview

Journal Sci Rep

Specialty Science

Date 2025 Jan 8

PMID 39775096

Authors

Kaili Chen

Huixin Liang

Zezhong Yu

Guangyao Guo

Huijian Zheng

Yun Huang

Liping Liu

Jie Lin

Jinlan Long

Renyao Pan

Xi Chen

Changgui Wang

Wenjie Zhang

Zhenshu Xu

Affiliations

Soon will be listed here.

Abstract

This retrospective study aimed to stress the advantages of autologous hematopoietic stem cell transplantation (auto-HSCT) in treating primary MM. Ninety-four MM patients who underwent initial parallel sequential auto-HSCT were selected. Data on efficacy (efficacy evaluation, renal function and hemoglobin recovery), immune reconstitution (B-cell subsets, immunoglobulin levels, T-cell subsets, NK cells, neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR)) and hematopoietic reconstitution times were collected and analyzed. Whether in all selected patients or in groups R-ISS II-III, there was a notable increase in the proportion of patients achieving in a very good partial response (VGPR) or better (P < 0.001, P = 0.02) and a complete response (CR) or better (P = 0.007, P = 0.014) after transplantation compared to the pre-transplant status. Post-Transplant Immune Reconstitution Analysis (Baseline vs. Pre-Transplant and Pre-Transplant vs. Post-Transplant): The level of CD19 + B cells, CD20 + B cells, CD22 + B cells, CD3 + T cells, IgG and LMR showed the same change trend, that is, it decreased before transplantation (P < 0.001, P < 0.001, P < 0.001, P < 0.001, P<0.007, P < 0.001) and then increased significantly after transplantation(P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001, P < 0.001). CD3 + CD4 + T cells from 545.97 (342.11,708.60)/µL to 342.93 (168.38, 475.52)/µL (P < 0.001) and then to 251.48 (188.52, 406.98)/µL (P = 0.348); CD3 + CD8 + T cells from 391.36 (242.19, 563.37)/µL to 337.23 (192.54, 505.96)/µL (P = 0.065) and then to 797.96 (514.49, 1198.03)/µL (P < 0.001), so the CD3 + CD4+/CD3 + CD8 + T cell ratio still remained inverted post-transplant. NK cells changed from 309.86 (206.33, 460.96)/µL to 258.31 (160.75, 436.68)/ µL (P = 0.229) and then to 151.08 (108.17, 240.84)/µL (P = 0.007). Auto-HSCT can promote prolonged remission in patients with MM and also overcome some high-risk factors to achieve superior efficacy in group R-ISS II-III. Patients were immunodeficient before transplantation and auto-HSCT facilitated immune reconstitution.

References

Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K . Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995; 13(10):2547-55. DOI: 10.1200/JCO.1995.13.10.2547. View

Saeed L, Patnaik M, Begna K, Al-Kali A, Litzow M, Hanson C . Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patients. Blood Cancer J. 2017; 7(3):e550. PMC: 5380913. DOI: 10.1038/bcj.2017.30. View

Mikkilineni L, Kochenderfer J . CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2020; 18(2):71-84. DOI: 10.1038/s41571-020-0427-6. View

Legrand N, Dontje W, Van Lent A, Spits H, Blom B . Human thymus regeneration and T cell reconstitution. Semin Immunol. 2007; 19(5):280-8. DOI: 10.1016/j.smim.2007.10.001. View

Goncalves T, Benvegnu D, Bonfanti G . Specific factors influence the success of autologous and allogeneic hematopoietic stem cell transplantation. Oxid Med Cell Longev. 2010; 2(2):82-7. PMC: 2763249. DOI: 10.4161/oxim.2.2.8355. View

Mielke S, Rezvani K, Savani B, Nunes R, Yong A, Schindler J . Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantation in elderly patients and association with acute graft-versus-host disease. Blood. 2007; 110(5):1689-97. PMC: 1975850. DOI: 10.1182/blood-2007-03-079160. View

Dhakal B, Szabo A, Chhabra S, Hamadani M, DSouza A, Usmani S . Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysis. JAMA Oncol. 2018; 4(3):343-350. PMC: 5885822. DOI: 10.1001/jamaoncol.2017.4600. View

Mateos M, Cavo M, Blade J, Dimopoulos M, Suzuki K, Jakubowiak A . Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2019; 395(10218):132-141. DOI: 10.1016/S0140-6736(19)32956-3. View

Wang J, Shi H, Fan Z, Yang J, Zheng Y, Zeng D . Prognostic nutritional index combined with NLR to construct a survival prediction model and decision analysis of patients with muscle-invasive bladder cancer after surgery. Cancer Med. 2023; 12(13):14207-14224. PMC: 10358268. DOI: 10.1002/cam4.6088. View

10.

Heck C, Steiner S, Kaebisch E, Frentsch M, Wittenbecher F, Scheibenbogen C . CD4+ T Cell Dependent B Cell Recovery and Function After Autologous Hematopoietic Stem Cell Transplantation. Front Immunol. 2021; 12:736137. PMC: 8519398. DOI: 10.3389/fimmu.2021.736137. View

11.

Jimenez-Zepeda V, Duggan P, Neri P, Chaudhry A, Tay J, Bahlis N . Immunoparesis and polyclonal immunoglobulin recovery after auto-SCT for patients with multiple myeloma treated at a single institution. Leuk Lymphoma. 2017; 59(8):1920-1926. DOI: 10.1080/10428194.2017.1403026. View

12.

Perez E, Orange J, Bonilla F, Chinen J, Chinn I, Dorsey M . Update on the use of immunoglobulin in human disease: A review of evidence. J Allergy Clin Immunol. 2017; 139(3S):S1-S46. DOI: 10.1016/j.jaci.2016.09.023. View

13.

Kyle R, Rajkumar S . Multiple myeloma. Blood. 2008; 111(6):2962-72. PMC: 2265446. DOI: 10.1182/blood-2007-10-078022. View

14.

Locatelli F, Lucarelli B, Merli P . Current and future approaches to treat graft failure after allogeneic hematopoietic stem cell transplantation. Expert Opin Pharmacother. 2013; 15(1):23-36. DOI: 10.1517/14656566.2014.852537. View

15.

Boyiadzis M, Memon S, Carson J, Allen K, Szczepanski M, Vance B . Up-regulation of NK cell activating receptors following allogeneic hematopoietic stem cell transplantation under a lymphodepleting reduced intensity regimen is associated with elevated IL-15 levels. Biol Blood Marrow Transplant. 2008; 14(3):290-300. DOI: 10.1016/j.bbmt.2007.12.490. View

16.

Olsson R, Remberger M, Schaffer M, Berggren D, Svahn B, Mattsson J . Graft failure in the modern era of allogeneic hematopoietic SCT. Bone Marrow Transplant. 2012; 48(4):537-43. DOI: 10.1038/bmt.2012.239. View

17.

Pulsipher M, Chitphakdithai P, Logan B, Leitman S, Anderlini P, Klein J . Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood. 2009; 114(13):2606-16. PMC: 2756121. DOI: 10.1182/blood-2009-03-208355. View

18.

Srinivasan R, Takahashi Y, McCoy J, Espinoza-Delgado I, Dorrance C, Igarashi T . Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation. Br J Haematol. 2006; 133(3):305-14. DOI: 10.1111/j.1365-2141.2006.06019.x. View

19.

Brown R, Murray A, Pope B, Sze D, Gibson J, Ho P . Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol. 2004; 125(6):743-8. DOI: 10.1111/j.1365-2141.2004.04984.x. View

20.

Liu J, Liu W, Mi L, Zeng X, Cai C, Ma J . Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016. J Hematol Oncol. 2019; 12(1):136. PMC: 6905074. DOI: 10.1186/s13045-019-0807-5. View